Single User License
INR 102255
Site License
INR 204510
Corporate User License
INR 306765

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Biomay AG-Product Pipeline Review-2015

Biomay AG-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Biomay AG-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Biomay AG-Product Pipeline Review-2015', provides an overview of the Biomay AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biomay AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Biomay AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Biomay AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Biomay AG's pipeline products

Reasons To Buy

Evaluate Biomay AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Biomay AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Biomay AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Biomay AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biomay AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Biomay AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Biomay AG Snapshot 5

Biomay AG Overview 5

Key Information 5

Key Facts 5

Biomay AG-Research and Development Overview 6

Key Therapeutic Areas 6

Biomay AG-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

Biomay AG-Pipeline Products Glance 12

Biomay AG-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Biomay AG-Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Biomay AG-Drug Profiles 15

BM-32 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

fish hypoallergenic vaccine 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

grass allergy vaccine 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

BM-31 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

BM-34 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

BM-35 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

BM-36 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Japanese cedar hypoallergenic vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ragweed hypoallergenic vaccine 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Biomay AG-Pipeline Analysis 25

Biomay AG-Pipeline Products by Route of Administration 25

Biomay AG-Pipeline Products by Molecule Type 26

Biomay AG-Recent Pipeline Updates 27

Biomay AG-Dormant Projects 28

Biomay AG-Locations And Subsidiaries 29

Head Office 29

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31

List of Tables

Biomay AG, Key Information 5

Biomay AG, Key Facts 5

Biomay AG-Pipeline by Indication, 2015 7

Biomay AG-Pipeline by Stage of Development, 2015 8

Biomay AG-Monotherapy Products in Pipeline, 2015 9

Biomay AG-Out-Licensed Products in Pipeline, 2015 10

Biomay AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 11

Biomay AG-Phase II, 2015 12

Biomay AG-Phase I, 2015 13

Biomay AG-Preclinical, 2015 14

Biomay AG-Pipeline by Route of Administration, 2015 25

Biomay AG-Pipeline by Molecule Type, 2015 26

Biomay AG-Recent Pipeline Updates, 2015 27

Biomay AG-Dormant Developmental Projects,2015 28

List of Figures

Biomay AG-Pipeline by Top 10 Indication, 2015 7

Biomay AG-Pipeline by Stage of Development, 2015 8

Biomay AG-Monotherapy Products in Pipeline, 2015 9

Biomay AG-Out-Licensed Products in Pipeline, 2015 10

Biomay AG-Pipeline by Top 10 Molecule Type, 2015 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Biomay AG; Biomay AG - Key Therapeutics; Biomay AG - Pipeline Overview and Promising Molecules; Biomay AG - News; Biomay AG - Latest Updates; Biomay AG - Pipeline; Biomay AG - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com